Citi Downgrades Synergy Pharmaceuticals (SGYP) to Sell
Tweet
Share
E-mail
Get Alerts SGYP Hot Sheet
Price: $0.03 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Citi downgraded Synergy Pharmaceuticals (NASDAQ: SGYP) from Neutral to Sell.
Analyst Liav Abraham says the attractiveness of the company as a takeout target has diminished following the recent launch of Trulance.
For an analyst ratings summary and ratings history on Synergy Pharmaceuticals click here. For more ratings news on Synergy Pharmaceuticals click here.
Shares of Synergy Pharmaceuticals closed at $4.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, Downgrades, Hot Downgrades, RumorsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
